This study reveals a distinct metabolic signature in patients with a highly malignant form of ovarian cancer that offers much needed new biomarkers for monitoring disease progression and patient outcome.

These findings shed new light on the role of macrophages during the early stages of tumor formation, demonstrating that their accumulation during wound healing and their gross consumption of arginine is a foreboding sign of tumor development.

These findings illuminate a signaling network that integrates hypoxic and innate immune responses in the tumor microenvironment, coordinating the creation of an immunosuppressive, prometastatic state that drives liver cancer progression.

This study provides mechanistic insights into the tumor suppressive role of the Y chromosome, in which epigenetic modification by a histone demethylase attenuates prostate cancer cell invasion, with potential implications for prognosis and treatment of metastatic disease.

These findings provide new mechanistic insights into the regulation of ROS production in colon cancer cells and offer new opportunities to investigate the therapeutic modulation of intracellular ROS levels in tumor cells.

This report defines increased chromosomal instability (CIN) as a newly identified outcome of many currently used anticancer drugs, with implications for the development of new therapeutic strategies that target and leverage the CIN phenotype in cancer cells.

Efficacious antitumor responses triggered by abazitaxel second-line chemotherapy for metastatic prostate cancer administered in combination with antiandrogens rely greatly on the status and responsiveness of the androgen receptor, with potential implications for patient stratification.

These findings provide preclinical evidence that miR-34a suppresses triple-negative breast cancer, supporting investigation to develop it as a targeted therapeutic strategy currently lacking in this disease.

This study shows how a genetic skin disorder rapidly progresses to an aggressive skin cancer, identifying promising therapeutic targets within the compromised dermal microenvironment that may limit carcinogenesis.